恩度联合顺铂治疗恶性心包积液疗效探讨

Observation on Curative Effect of Endostar and Cis-platinum in Treatment of Malignant Pericardial Effusion

目的探讨恩度(重组人血管内皮抑制素)联合顺铂心包腔灌注治疗恶性心包积液的疗效及安全性。方法方便选取2011年9月—2015年9月该院经病理确诊为恶性肿瘤合并有心包积液54例患者按随机化原则分为2组;A组患者恩度联合顺铂心包腔内灌注治疗;B组患者单药恩度心包腔内灌注治疗,每周1次,最多连续用药3周。比较两组之间的疗效、生活质量改善情况及不良反应。结果 A组完全缓解率75.9%(22/29),B组完全缓解率48.0%(12/25),差异有统计学意义(P<0.05),但两组总有效率相似,差异无统计学意义,且A组生活质量改善较B组明显(P<0.05)。结论恩度联合顺铂治疗恶性心包积液疗效好,毒副反应小,且改善生存质量,值得临床推广应用。

Objective To observe the curative effect and safety of endostar（homemade human rh-endostatin） and cis-platinum pericardial cavity perfusion treatment for malignant pericardial effusion. Methods 54 cases of patients with malignant tumors and pericardial effusion diagnosed by pathology in our hospital from September 2011 to September 2015 were randomly divided into two groups, the group A were treated with endostar and cis-platinum pericardial cavity perfusion once a week, the group B were treated with endostar pericardial cavity perfusion once a week, the continuous medication was 3weeks at most, and the curative effects, improvement of quality of life and adverse reactions were compared between the two groups. Results The difference in the complete remission rate between the group A and the group B had statistical significance, [75.9%（22/29） vs 0%（12/25）], P〈0.05, but the total effective rates of the two groups were similar and the difference had no statistical significance, and the improvement of quality of life in the group A was more obvious than that in the group B, P〈0.05. Conclusion The curative effect of endostar and cis-platinum in treatment of malignant pericardial effusion is good with small toxic and side effect, and it can improve the survival quality, which is worth clinical promotion and application.